The double-edged sword of AlloHCT for SCD

1Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Ghannam and colleagues report on the development of myeloid malignancy in 3 individuals with homozygous sickle cell disease (SCD).1 This represented a total of 4% (3 of 76) of their cohort transplanted for SCD from 2004 to 2018. Participants with severe SCD had 4 common features: (1) before transplant, clonal hematopoiesis of indeterminate potential (CHIP)- related mutations were detected in the blood of both individuals assessed; (2) all received nonmyeloablative, allogeneic hematopoietic cell transplant (AlloHCT) using total body irradiation (TBI) (300 to 400 cGy) and alemtuzumabbased conditioning; (3) participants received mobilized peripheral blood stem cells; (4) the myeloid malignancy occurred 2 to 5 years after a failed allograft. 2020 by The American Society of Hematology

Cite

CITATION STYLE

APA

Kassim, A. A. (2020, April 2). The double-edged sword of AlloHCT for SCD. Blood. American Society of Hematology. https://doi.org/10.1182/BLOOD.2020005118

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free